Trials / Completed
CompletedNCT00486252
Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®
Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN® (Latanoprost) as First-Line Monotherapy and as Second-Line Monotherapy After Beta-Blockers Therapy Failure
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 996 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to evaluate the Intraocular pressure reducing effect of Xalatan over 3 months. The secondary objective is to study the other efficacy parameters during treatment for 3 months
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observational | This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed. |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2007-06-14
- Last updated
- 2021-03-01
- Results posted
- 2009-07-16
Source: ClinicalTrials.gov record NCT00486252. Inclusion in this directory is not an endorsement.